KR940005278A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR940005278A
KR940005278A KR1019930008442A KR930008442A KR940005278A KR 940005278 A KR940005278 A KR 940005278A KR 1019930008442 A KR1019930008442 A KR 1019930008442A KR 930008442 A KR930008442 A KR 930008442A KR 940005278 A KR940005278 A KR 940005278A
Authority
KR
South Korea
Prior art keywords
cis
pharmaceutical composition
retinoic acid
acitretin
vitamin
Prior art date
Application number
KR1019930008442A
Other languages
English (en)
Inventor
볼라그 베르너
브록크하우스 만프레트
훈지커 빌리
Original Assignee
프리돌린 클라우스너·롤란트 보러
에프. 호프만-라 로 슈에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너·롤란트 보러, 에프. 호프만-라 로 슈에이지 filed Critical 프리돌린 클라우스너·롤란트 보러
Publication of KR940005278A publication Critical patent/KR940005278A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 활성성분으로서 9-시스-또는 13-시스-레티노산 또는 아시트레틴, 약제학적으로 유용한 이의 염 또는 이의 에스테르 및 비타민 D 유도체를 통상의 약제학적 담체를 함유하는 약제학적 제제에 관한 것이다.

Description

약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 9-시스 레티노산과 칼시트리올을 투여했을 경우의 HL 60 세포의 분화를 나타낸 그래프이다.

Claims (2)

  1. 활성성분으로서 9-시스- 또는 13-시스-레티노산 또는 아시트레틴, 약제학적으로 유용한 이의 염 또는 이의 에스테르 및 비타민 D 유도체를 함유하고 통상의 약제학적 담체를 함유하는 약제학적 제제.
  2. 제1항에 있어서, 활성성분이 9-시스-레티노산 및 칼시트리올인 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930008442A 1992-05-20 1993-05-18 약제학적 조성물 KR940005278A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH161992 1992-05-20
CH01619/92-5 1992-05-20
CH92693 1993-03-26
CH00926/93-5 1993-03-26

Publications (1)

Publication Number Publication Date
KR940005278A true KR940005278A (ko) 1994-03-21

Family

ID=25686129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930008442A KR940005278A (ko) 1992-05-20 1993-05-18 약제학적 조성물

Country Status (12)

Country Link
EP (1) EP0579915A1 (ko)
JP (1) JPH0632740A (ko)
KR (1) KR940005278A (ko)
CN (1) CN1080525A (ko)
AU (1) AU3716193A (ko)
CA (1) CA2096196A1 (ko)
CZ (1) CZ83293A3 (ko)
HU (1) HUT66864A (ko)
IL (1) IL105700A0 (ko)
NO (1) NO931831L (ko)
NZ (1) NZ247630A (ko)
TW (1) TW272187B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461622B2 (en) * 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
DK128494A (da) * 1994-11-08 1996-05-09 Edel K Seidenschnur Behandling af keratinøse og psoriatiske sygdomstilstande med neglelak indeholdende vitamin D metabolit, eller derivat, og/eller vitamin A derivat
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
AU6944796A (en) * 1995-09-28 1997-04-17 Teijin Limited Preventive or remedy for hyperthyreosis
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
EP0815858B1 (en) * 1996-07-01 2001-08-22 Nisshin Flour Milling Co., Ltd. Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-alpha-tocopherol ester
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
US8541469B2 (en) 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
US6339107B1 (en) 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
JP2002104995A (ja) * 2000-09-29 2002-04-10 Masahiko Hosaka テロメラーゼ活性抑制剤
JP4326159B2 (ja) 2001-02-09 2009-09-02 株式会社ジェイテクト 玉軸受
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
MXPA05012632A (es) * 2003-05-20 2006-02-22 Ranbaxy Lab Ltd Composiciones farmaceuticas de acitretin.
WO2005102296A2 (en) * 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
CN102727476B (zh) * 2012-06-14 2014-05-14 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治骨质疏松药物中的应用
JP2019014676A (ja) * 2017-07-06 2019-01-31 東海カプセル株式会社 カプセル剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360910A (ja) * 1986-09-01 1988-03-17 Shiseido Co Ltd 皮膚外用剤

Also Published As

Publication number Publication date
CN1080525A (zh) 1994-01-12
JPH0632740A (ja) 1994-02-08
CA2096196A1 (en) 1993-11-21
TW272187B (ko) 1996-03-11
EP0579915A1 (de) 1994-01-26
NZ247630A (en) 1995-12-21
IL105700A0 (en) 1993-09-22
NO931831L (no) 1993-11-22
AU3716193A (en) 1993-11-25
CZ83293A3 (en) 1993-12-15
NO931831D0 (no) 1993-05-19
HUT66864A (en) 1995-01-30
HU9301404D0 (en) 1993-09-28

Similar Documents

Publication Publication Date Title
KR940005278A (ko) 약제학적 조성물
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
DE3579128D1 (de) 13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel.
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
KR880009662A (ko) Igf-ii함유 약제
FR2715565B1 (fr) Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
ATE163849T1 (de) Arzneimittel enthaltend als wirkstoff r-alpha- liponsäure oder s-alpha-liponsäure
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
DE69112914D1 (de) Herstellungsverfahren von Mikrokugeln.
KR900017590A (ko) 좌창(Acne)치료방법 및 그 약제 조성물
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
GB1298494A (en) Phenylethanolamine derivatives
HUP9903855A2 (hu) Orális adagolásra való valproesavat tartalmazó gyógyszerészeti mikrogömbök
AU621763B2 (en) Stable tretinoin emulsified cream formulations
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
KR910016674A (ko) 신규한 레티노이드
US4837213A (en) Pharmaceutical vehicle for active substances in the form of an anhydrous gel
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
KR920700624A (ko) 피부도포용 수용성 비타민 a제제
EP0162924A4 (en) 5-FLUORURACILA COMBS AND MEDICAL COMPOSITIONS CONTAINING THEM.
IL108246A (en) (all-e)-3,7-dimethyl-9-(3, 5-dimethyl- 2-nonyloxyphenyl)-2, 4, 6, 8-nonatetraenoic acid derivatives, their preparation and pharmaceutical compositions containing them
GB1449404A (en) N-arylsulphonyl urea derivatives

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid